| gefitinib / Generic mfg. |
NCT00005806: Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer |
|
|
| Completed | 1 | | US | carboplatin, gefitinib, paclitaxel | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Lung Cancer | 03/02 | 03/02 | | |
NCT00040781: Gefitinib in Treating Children With Refractory Solid Tumors |
|
|
| Completed | 1 | 45 | US | gefitinib, Iressa, ZD 1839, pharmacological study, pharmacological studies, laboratory biomarker analysis | National Cancer Institute (NCI) | Unspecified Childhood Solid Tumor, Protocol Specific | 10/04 | | | |
NCT00027625: Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma |
|
|
| Completed | 1 | | US | gefitinib, temozolomide | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI) | Brain and Central Nervous System Tumors | 03/05 | 11/05 | | |
NCT00252798: ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer |
|
|
| Completed | 1 | 44 | RoW | Gefitinib, Carboplatin, Paclitaxel, Radiation | AstraZeneca | Non Small Cell Lung Carcinoma | | 10/05 | | |
NCT00162318: A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer |
|
|
| Completed | 1 | 30 | US | Cetuximab + Gefitinib, Erbitux | Eli Lilly and Company | Non-Small-Cell Lung Carcinoma | 04/06 | 04/06 | | |
NCT00255489: A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer |
|
|
| Completed | 1 | 36 | Europe | Gefitinib, palliative thoracic radiotherapy | AstraZeneca | Non-small-cell Lung Cancer | | 06/06 | | |
NCT00502060: Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer |
|
|
| Completed | 1 | 65 | Europe | AZD2171, ZD1839 | AstraZeneca | Advanced Tumor | 06/06 | 06/06 | | |
NCT00185835: Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck |
|
|
| Completed | 1 | 10 | US | ZD-1839, Cisplatin | Stanford University, American Society of Clinical Oncology, AstraZeneca | Head and Neck Cancer, Carcinoma, Squamous Cell | 07/06 | | | |
NCT00084786: Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | | US | docetaxel, gefitinib | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 07/06 | | | |
NCT00084708: Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 53 | US | calcitriol, dexamethasone, gefitinib | Roswell Park Cancer Institute | Unspecified Adult Solid Tumor, Protocol Specific | 10/06 | 05/07 | | |
NCT00026364: ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer |
|
|
| Completed | 1 | 22 | US | fluorouracil, gefitinib, irinotecan hydrochloride, leucovorin calcium | National Cancer Institute (NCI) | Colorectal Cancer | 12/06 | | | |
NCT00039390: Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 41 | US | capecitabine, CAPE, Ro 09-1978/000, Xeloda, gefitinib, Iressa, ZD 1839, pharmacological study, pharmacological studies, laboratory biomarker analysis | National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 05/07 | | | |
NCT00310154: Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer |
|
|
| Completed | 1 | 45 | US | docetaxel, gefitinib, laboratory biomarker analysis, radiation therapy | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Lung Cancer | 07/07 | 08/10 | | |
NCT00820417: Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib |
|
|
| Completed | 1 | 63 | Europe | Cetuximab/Gefitinib combination and/or monotherapy | Harrison Clinical Research, Merck KGaA, Darmstadt, Germany, AstraZeneca | Colorectal Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer (NSCLC) | 09/07 | 05/08 | | |
AGUS, NCT00127829: Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic |
|
|
| Completed | 1 | 66 | US | Gefitinib, IRESSA® | AstraZeneca | Tumors | | 01/08 | | |
NCT00328562: ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer |
|
|
| Completed | 1 | 13 | US | ZD1839 (Iressa), Thoracic Radiotherapy | Sidney Kimmel Cancer Center at Thomas Jefferson University, AstraZeneca | Non-Small Cell Lung Carcinoma (NSCLC) | 04/08 | 09/10 | | |
NCT00497250: Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy |
|
|
| Unknown status | 1 | 32 | RoW | Gefitinib, Iressa@, Radiation Therapy, 3-D CRT and IMRT | Fudan University | Carcinoma, Non-Small-Cell Lung | 03/09 | 10/09 | | |
IRESSA&H&N, NCT00681967: Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer |
|
|
| Completed | 1 | 30 | Europe | Gefitinib, IRESSA (TM) | AstraZeneca | Head and Neck Cancer | 10/09 | 10/09 | | |
NCT00186979: Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors |
|
|
| Completed | 1 | 34 | US | Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime. | St. Jude Children's Research Hospital, AstraZeneca, National Institutes of Health (NIH) | Solid Tumors | 03/10 | 03/10 | | |
NCT00033449: Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer |
|
|
| Terminated | 1 | 30 | US | gefitinib, Iressa, ZD 1839, radiation therapy, irradiation, radiotherapy, therapy, radiation, cisplatin, CACP, CDDP, CPDD, DDP, laboratory biomarker analysis | National Cancer Institute (NCI) | Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx | 04/10 | | | |
NCT00083057: Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck |
|
|
| Completed | 1 | 30 | US | gefitinib, paclitaxel, radiation therapy | National Institutes of Health Clinical Center (CC), National Cancer Institute (NCI) | Head and Neck Cancer | 10/10 | 11/10 | | |
ACTRN12610000684022: Combination Gefitinib and Methotrexate to Medically Treat Ectopic Pregnancies: A Phase I Clinical Toxicity Trial. |
|
|
| Completed | 1 | 12 | | | Dr Stephen Tong, Monash Institute of Medical Research | Clinically stable ectopic pregnancies | | | | |
NCT00132158: ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors |
|
|
| Completed | 1 | 19 | US | Irinotecan (Camptosar), Gefitinib (Iressa) | St. Jude Children's Research Hospital, AstraZeneca | Glioblastoma, Rhabdomyosarcomas, Neuroblastoma, Osteosarcoma | 10/11 | 10/11 | | |
ACTRN12611000104954: Combination Gefitinib and Methotrexate for the Treatment of Persistent Gestational Trophoblastic Disease: A Phase I Clinical Trial |
|
|
| Terminated | 1 | 12 | | | Miss Orla McNally, Director Gynaecological Oncology & Dysplasia, Monash Institute of Medical Research Flagship Grant, Monash University | Persistent Gestational Trophoblastic Disease | | | | |
NCT00372515: High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations |
|
|
| Completed | 1 | 7 | US | Gefitinib, Iressa | David M. Jackman, MD, AstraZeneca, Massachusetts General Hospital | Non-Small Cell Lung Cancer | 12/12 | 04/15 | | |
| Completed | 1 | 171 | US, Europe | Cetuximab, BIBW 2992 | Boehringer Ingelheim | Carcinoma, Non-Small-Cell Lung | 01/13 | 08/14 | | |
NCT01147211: Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC) |
|
|
| Unknown status | 1 | 21 | RoW | MK2206 | National Taiwan University Hospital | Non Small Cell Lung Cancer | 07/13 | 12/13 | | |
|
NCT01602289: A Study of LY2875358 in Japanese Participants With Advanced Cancer |
|
|
| Completed | 1 | 17 | Japan | LY2875358, Erlotinib, Gefitinib | Eli Lilly and Company | Solid Tumors, Lymphoma, Carcinoma, Non-Small-Cell Lung | 08/14 | 08/14 | | |
NCT00993499: Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib |
|
|
| Completed | 1 | 44 | Europe | BIBW 2992, Sirolimus (rapamycin) | Boehringer Ingelheim | Carcinoma, Non-Small-Cell Lung | 09/14 | 09/14 | | |
NCT02157883: Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) |
|
|
| Completed | 1 | 39 | Europe, US, RoW | Pharmacokinetic sampling, AZD9291, Itraconazole | AstraZeneca | Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer | 04/15 | 05/23 | | |
NCT01570296: A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR |
|
|
| Completed | 1 | 38 | RoW | Gefitinib and BKM120 | National Cancer Centre, Singapore, Novartis | Non-Small Cell Lung Cancer, Solid Tumors | 02/16 | 12/18 | | |
|
GEFTREM, NCT02040064: Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients |
|
|
| Completed | 1 | 27 | Europe | Gefitinib, Tremelimumab | Gustave Roussy, Cancer Campus, Grand Paris, AstraZeneca | Non Small Cell Lung Cancer | 03/16 | 03/16 | | |
|
|
CURCUMIN, NCT02321293: A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC |
|
|
| Unknown status | 1 | 20 | Canada | CurcuVIVA™, Curcumin, Tyrosine Kinase Inhibitor gefitinib (Iressa), gefitinib (Iressa), Tyrosine Kinase Inhibitor erlotinib (Tarceva), erlotinib (Tarceva) | Lady Davis Institute, Jewish General Hospital | Lung Cancer | 08/16 | 12/16 | | |
NCT03050164: Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions |
|
|
| Completed | 1 | 38 | NA | Gefitinib Tablet 250mg of Hunan Kelun, A031, Iressa® Tablet 250mg of AZN, Iressa® | Hunan Kelun Pharmaceutical Co., Ltd. | Bioequivalence Study | 11/16 | 11/16 | | |
NCT03050177: Bioequivalence Study of Gefitinib Tablets Under Fed Conditions |
|
|
| Completed | 1 | 38 | NA | Gefitinib Tablet 250mg of Hunan Kelun, A031, Iressa® Tablet 250mg of AZN, Iressa® | Hunan Kelun Pharmaceutical Co., Ltd. | Healthy | 12/16 | 12/16 | | |
ChiCTR-IIR-16009492: An open label, randomized, single-dose, two-period, two-sequence, crossover pivotal study to assess the bioequivalence of Gefitinib Tablets 250mg in healthy adult subjects under fasting/ Fed condition |
|
|
| Recruiting | 1 | 90 | | Phase I: CTTQ Gefitinib Tablets 250mg; Phase II: reference Gefitinib Tablets 250mg ;Phase I: reference Gefitinib Tablets 250mg; Phase II: CTTQ Gefitinib Tablets 250mg ;Phase I: CTTQ Gefitinib Tablets 250mg; Phase II: reference Gefitinib Tablets 250mg ;Phase I: reference Gefitinib Tablets 250mg; Phase II: CTTQ Gefitinib Tablets 250mg | The first hospital of jilin university; CTTQ, CTTQ | NSCLC | | | | |
NCT02374645: A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC |
|
|
| Completed | 1 | 64 | RoW | Volitinib, AZD6094, HMPL-504, gefitinib, Iressa, ZD1839 | Hutchison Medipharma Limited, AstraZeneca | Non-Small Cell Lung Cancer | 02/18 | 09/18 | | |
|
|
VICTORY-J, NCT02151721: Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer |
|
|
| Unknown status | 1 | 12 | Japan | Vorinostat, gefitinib, Zolinza, Iressa | Kanazawa University | Non-Small-Cell Lung Carcinoma | 02/18 | 02/18 | | |
NCT03602027: Phase I Study of the Combination of Anlotinib With Gefitinib |
|
|
| Unknown status | 1 | 9 | NA | Anlotinib, Gefitinib | Second Affiliated Hospital of Nanchang University | Non-squamous Non-small Cell Lung Cancer | 12/18 | 02/19 | | |
NCT03050411: Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer |
|
|
| Unknown status | 1 | 30 | RoW | Apatinib Mesylate Tablets, EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib) | Peking University Third Hospital | Nonsmall Cell Lung Cancer | 06/19 | 10/19 | | |
ChiCTR2300074939: Clinical study protocol for the bioequivalence trial of gefitinib tablets in humans |
|
|
| Completed | 1 | 82 | | Subjects took the test preparation in the first cycle, and took the reference preparation in the second cycle ;Subjects took the reference preparation in the first cycle, and took the test preparation in the second cycle ;In the postprandial state, the subjects took the test preparation in the first cycle and took the reference preparation in the second cycle ;In the postprandial state, the subjects took the reference preparation in the first cycle and took the test preparation in the second cycle | Huzhou Central Hospital, Zhejiang Province; Furen Pharmaceutical Group Co., Ltd, Furen Pharmaceutical Group Co., Ltd | lung cancer | | | | |
NCT03599518: DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer |
|
|
| Terminated | 1 | 20 | Japan | DS-1205c, Experimental product, Gefitinib | Daiichi Sankyo Co., Ltd. | Non Small Cell Lung Cancer | 04/20 | 06/20 | | |
NCT04390984: Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients |
|
|
| Recruiting | 1 | 22 | RoW | Apatinib Mesylate, Gefitinib | Jiangsu HengRui Medicine Co., Ltd. | NSCLC | 02/21 | 03/21 | | |
NCT02088112: MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). |
|
|
| Completed | 1 | 56 | Japan, US, RoW | Gefitinib, MEDI4736 | MedImmune LLC, AstraZeneca | Carcinoma, Non-Small-Cell Lung | 03/21 | 03/21 | | |
|
|
|
|
|
NCT03333343: Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC |
|
|
| Active, not recruiting | 1 | 105 | Europe, Canada, RoW | EGF816, trametinib, ribociclib, LXH254, INC280, gefitinib | Novartis Pharmaceuticals | EGFR-mutant Non-small Cell Lung Cancer | 12/24 | 12/24 | | |
